Compare Stocks: ENVB, DARE, PLRZ, and CLRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$2.60 +4.8%	$2.56	$2.20 ▼ $6.52	$20.78M	0.55	38,496 shs	46,566 shs
DARE Dare Bioscience	$0.93 -32.1%	$1.74	$0.77 ▼ $3.78	$14.02M	1.08	502,329 shs	8.00 million shs
ENVB Enveric Biosciences	$1.54 +1.7%	$1.44	$1.25 ▼ $17.64	$5.65M	1.13	122,869 shs	55,644 shs
PLRZ Polyrizon	$10.98 +2.1%	$12.50	$2.88 ▼ $18.20	$22.88M	-1.5	62,767 shs	63,735 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	0.00%	+1.17%	+0.78%	-15.86%	-41.18%
DARE Dare Bioscience	0.00%	-33.57%	-52.06%	-57.14%	-55.92%
ENVB Enveric Biosciences	0.00%	-0.97%	+12.87%	-31.78%	-88.48%
PLRZ Polyrizon	0.00%	+0.50%	-15.54%	-25.81%	+81.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$2.60 +4.8%	$2.56	$2.20 ▼ $6.52	$20.78M	0.55	38,496 shs	46,566 shs
DARE Dare Bioscience	$0.93 -32.1%	$1.74	$0.77 ▼ $3.78	$14.02M	1.08	502,329 shs	8.00 million shs
ENVB Enveric Biosciences	$1.54 +1.7%	$1.44	$1.25 ▼ $17.64	$5.65M	1.13	122,869 shs	55,644 shs
PLRZ Polyrizon	$10.98 +2.1%	$12.50	$2.88 ▼ $18.20	$22.88M	-1.5	62,767 shs	63,735 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	0.00%	+1.17%	+0.78%	-15.86%	-41.18%
DARE Dare Bioscience	0.00%	-33.57%	-52.06%	-57.14%	-55.92%
ENVB Enveric Biosciences	0.00%	-0.97%	+12.87%	-31.78%	-88.48%
PLRZ Polyrizon	0.00%	+0.50%	-15.54%	-25.81%	+81.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	323.08% Upside
DARE Dare Bioscience	2.33	Hold	$10.00	975.27% Upside
ENVB Enveric Biosciences	1.00	Sell	N/A	N/A
PLRZ Polyrizon	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ENVB, DARE, PLRZ, and CLRB Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/29/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	CLRB Cellectar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	ENVB Enveric Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/12/2026	CLRB Cellectar Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/21/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$1.89 per share	N/A
DARE Dare Bioscience	$1.03M	13.62	N/A	N/A	$0.20 per share	4.65
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$7.00 per share	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$13.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-365.85%	-164.45%	10/29/2026 (Estimated)
DARE Dare Bioscience	-$13.40M	-$0.95	N/A	N/A	N/A	-803.80%	-512.31%	-36.20%	N/A
ENVB Enveric Biosciences	-$8.77M	-$23.54	N/A	N/A	N/A	N/A	-220.97%	-177.47%	8/17/2026 (Estimated)
PLRZ Polyrizon	-$3.34M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ENVB, DARE, PLRZ, and CLRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ENVB Enveric Biosciences	N/A	-$0.76	N/A	-$0.76	N/A	N/A
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLRB Cellectar Biosciences	N/A	1.90	1.90
DARE Dare Bioscience	N/A	1.03	1.03
ENVB Enveric Biosciences	N/A	11.66	11.66
PLRZ Polyrizon	N/A	29.03	29.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLRB Cellectar Biosciences	16.41%
DARE Dare Bioscience	6.70%
ENVB Enveric Biosciences	13.82%
PLRZ Polyrizon	N/A

Insider Ownership

Company	Insider Ownership
CLRB Cellectar Biosciences	2.58%
DARE Dare Bioscience	4.10%
ENVB Enveric Biosciences	2.41%
PLRZ Polyrizon	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLRB Cellectar Biosciences	10	7.99 million	7.79 million	No Data
DARE Dare Bioscience	30	15.08 million	14.46 million	Not Optionable
ENVB Enveric Biosciences	20	3.68 million	3.59 million	Not Optionable
PLRZ Polyrizon	N/A	2.08 million	N/A	N/A

ENVB, DARE, PLRZ, and CLRB Headlines

Recent News About These Companies

Polyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026

July 13, 2026 | tipranks.com

Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray

July 2, 2026 | tipranks.com

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)

July 2, 2026 | msn.com

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting ...

July 2, 2026 | enidnews.comE

Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray

July 2, 2026 | quiverquant.comQ

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

July 2, 2026 | globenewswire.com

Polyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker Trial

June 29, 2026 | tipranks.com

Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy Blocker

June 29, 2026 | quiverquant.comQ

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

June 29, 2026 | globenewswire.com

Polyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery Patent

June 17, 2026 | tipranks.com

Polyrizon Ltd.: Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

June 17, 2026 | finanznachrichten.de

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

June 17, 2026 | globenewswire.com

Polyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA Pathway

June 15, 2026 | tipranks.com

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

June 15, 2026 | globenewswire.com

Polyrizon Ltd.: Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

June 12, 2026 | finanznachrichten.de

Polyrizon Marches on European Patent

June 11, 2026 | baystreet.ca

Polyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery Platform

June 10, 2026 | tipranks.com

Polyrizon Ltd. Announces Publication of European Patent Application for Innovative Nasal Drug Delivery Technology

June 10, 2026 | quiverquant.comQ

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

June 10, 2026 | globenewswire.com

Polyrizon Sets July 13, 2026 AGM to Vote on Board, Pay and Auditor Mandates

June 8, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ENVB, DARE, PLRZ, and CLRB Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

$2.60 +0.12 (+4.84%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.58 -0.02 (-0.58%)

As of 08/14/2026 07:58 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Dare Bioscience NASDAQ:DARE

$0.93 -0.44 (-32.12%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.90 -0.03 (-3.33%)

As of 08/14/2026 08:00 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Enveric Biosciences NASDAQ:ENVB

$1.54 +0.03 (+1.66%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.54 +0.01 (+0.52%)

As of 08/14/2026 07:56 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Polyrizon NASDAQ:PLRZ

$10.98 +0.23 (+2.14%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$10.74 -0.24 (-2.14%)

As of 08/14/2026 07:34 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENVB, DARE, PLRZ, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENVB, DARE, PLRZ, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENVB, DARE, PLRZ, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENVB, DARE, PLRZ, and CLRB Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

Dare Bioscience NASDAQ:DARE

Enveric Biosciences NASDAQ:ENVB

Polyrizon NASDAQ:PLRZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENVB, DARE, PLRZ, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENVB, DARE, PLRZ, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENVB, DARE, PLRZ, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENVB, DARE, PLRZ, and CLRB Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

Dare Bioscience NASDAQ:DARE

Enveric Biosciences NASDAQ:ENVB

Polyrizon NASDAQ:PLRZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools